Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

ABSTRACT:

Background

In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel, as compared with placebo, trastuzumab, and docetaxel. Overall survival was significantly improved with pertuzumab in an interim analysis without the median being reached. We report final prespecified overall survival results with a median follow-up of 50 months.

Methods

We randomly assigned patients with metastatic breast cancer who had not received previous chemotherapy or anti-HER2 therapy for their metastatic disease to receive the pertuzumab combination or the placebo combination. The secondary end points of overall survival, inv

SUBMITTER: Swain SM 

PROVIDER: S-EPMC5584549 | biostudies-literature | 2015 Feb

REPOSITORIES: biostudies-literature